Private equity investment in healthcare hit a record $191 billion in 2025. But as more investors crowd into the sector, competition for high-quality assets is intensifying, driving up prices and increasing pressure to deliver successful exits.
Matt Holt, former New Mountain Capital executive, is exploring a $30 billion deal to combine five health tech startups into a single platform called Thoreau. The venture would set out to simplify and integrate services across payers, providers and data — and if completed, it would rank among the largest private equity-backed health tech companies ever. Time will tell if this massive consolidation ever gets completed or translates into real value — or if it's just another bet on scale.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Walgreens has completed its sale to private equity firm Sycamore Partners, raising concerns that the deal could lead to widespread store closures, layoffs and reduced access to healthcare in vulnerable communities.
A new report from the Private Equity Stakeholder Project reveals that private equity firms have been increasingly acquiring intellectual and developmental disability providers and implementing cost-cutting strategies that reduce care quality.
We cannot simply accept this status quo and leave an entire generation of children unsupported when more viable options are available.
Walgreens is selling itself to the private equity firm Sycamore Partners. This comes after the company has faced increased competition from online retailers like Amazon. It remains to be seen, however, if Walgreens will perform better under Sycamore Partners.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B.
The impact of private equity investments in healthcare under the new administration is multifaceted. While deregulation and business-friendly policies could stimulate investment and drive innovation, there are significant concerns about the potential negative effects on healthcare quality and access.
CDMO Avid Bioservices is being acquired by the private equity firms GHO Capital Partners and Ampersand Capital Partners. Avid specializes in manufacturing biologic products for companies at all stages of development.
Baxter International is selling its kidney care business for less than it was able to fetch for its much smaller biopharma solutions segment last year. A unit within kidney care took a goodwill impairment charge, Baxter’s financial reports show.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Two senators recently introduced a bill that seeks to regulate private equity firms’ involvement in the healthcare industry. If passed, the act would establish a criminal penalty of up to six years in prison for private equity executives whose business decisions result in a patient’s death.
Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned. The research comes as concerns about PE-owned hospitals are intensifying — from leaders both within and outside of the healthcare industry.
This week, two bipartisan members of the Senate Budget Committee launched an investigation into private equity and its impact on healthcare. They initiated the probe to get answers about “questionable financial transactions” that could be hurting care quality for patients at hospitals owned by private equity firms.
In an interview, Nathan Ray, a partner with the healthcare and life practice who oversees M&A/PE related work in that industry for West Monroe, highlighted how his firm works with companies to drive due diligence for clients, and help acquired companies address issues and differentiate during holds.
Baxter International is selling its biopharma solutions business to private equity firms. The transaction is part of a broader trend in which life science firms are spinning out or selling operations in order to hone the focus of the remaining business on certain areas.